Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe

Reacquiring rights to omaveloxolone from AbbVie looks great business

 
• By Kevin Grogan
Chart_Sketch
Reata stock is on the up on Friedreich’s ataxia data • Source: Shutterstock

More from Rare Diseases

More from Scrip